Overview

20/20 GeneSystems Inc. is a developer of a protein array platform for pharmaceutical research and laboratory medicine. The layered proteomics technology is among the first techniques for simultaneously detecting expression and localization of numerous proteins in tissue from a single diseased biological sample.

The company began operations in June 2000 with exclusively licensed technology, which was developed at the National Institutes of Health, and is in co-development with the National Cancer Institute. 20/20 launched its first proteomics kit product in September 2001, to biomedical researchers at universities, federal labs and biotechnology companies.

20/20 is using variants of layered proteomics in-house for collaborations with pharmaceutical companies in the areas of target validation and clinical trials assay development. Eventually, layered proteomics will be used in clinical diagnostics to help tailor drugs to patients based on their disease proteome. 20/20 also recently began development of a rapid deployable multi-pathogen detection kit for use in bioterrorism defense.

Partners

Bioinformatics/software development: Bear Codes LLC and unnamed bioinformatics company.

Cooperative Research and Development Agreement: the National Cancer Institute.

Beta Test Agreements: Bristol-Myers Squibb Co., Novartis, the American Red Cross and several biotech companies, government labs and universities.